Overview

Tempest Therapeutics, Inc. (TPST), a clinical-stage oncology company, has released its Annual Report for fiscal year ended December 31, 2025. This report contains several significant developments, strategic updates, and financial highlights that are highly relevant for investors and shareholders.

Key Points & Price-Sensitive Developments

• Major Asset Acquisition: On February 3, 2026, Tempest completed the acquisition of assets from Erigen, issuing 8,268,495 shares of common stock to Erigen. This acquisition is expected to bring new synergy and growth opportunities to Tempest’s pipeline, marking a strategic shift in business focus.
• Capital-Efficient Development Strategy: Post-acquisition, Tempest is prioritizing a capital-efficient approach, seeking external funding, partnerships, and staged investments based on clinical and regulatory milestones. This could extend the company’s operational runway and support parallel development of multiple programs.
• Pipeline Expansion: The acquisition and new strategy are expected to enable development across several oncology programs, potentially accelerating Tempest’s presence in the clinical-stage biopharma sector. Specific pipeline details and program prioritization are being informed by ongoing data and regulatory feedback.
• Public Float and Shares Outstanding: As of June 30, 2025, Tempest’s public float was approximately \$30.1 million based on a closing price of \$6.80 per share. As of March 25, 2026, there are 14,344,034 shares of common stock outstanding. This substantial issuance related to the asset acquisition may impact share value and dilution considerations for existing shareholders.
• Regulatory Compliance and Reporting: Tempest confirms full compliance with SEC reporting requirements, has submitted all Interactive Data Files, and is classified as a smaller reporting company. The company is not an emerging growth company and does not qualify as a well-known seasoned issuer.
• Risk Factors & Forward-Looking Statements: The company highlights substantial risks and uncertainties, including those related to clinical development, regulatory approval, commercialization, funding, market fluctuations, and competition. Forward-looking statements are subject to change and are based on current information and expectations.
• Competition & Manufacturing: Tempest operates in a highly competitive sector. Manufacturing processes are tightly regulated, and the company maintains compliance through rigorous audits and quality assurance. Any disruption in manufacturing or competitive positioning can affect business outcomes.
• No Error Corrections or Restatements: The financial statements included in this filing do not reflect corrections of prior errors or restatements that would require recovery analysis of incentive-based compensation.
• Shareholder Information:
  • Shares listed on Nasdaq Stock Market LLC under the symbol TPST.
  • Securities registered pursuant to Section 12(b): Common Stock and Series A Junior Participating Preferred Purchase Rights.
  • No securities registered under Section 12(g).

Important Considerations for Shareholders

• Dilution Impact: The major share issuance to Erigen for the asset acquisition will significantly dilute existing shareholders, which may affect per-share valuations and ownership percentages.
• Strategic Shift: Tempest’s new capital-efficient strategy and asset portfolio expansion could change its risk profile and growth trajectory, making it attractive for new investors but potentially affecting current valuation assumptions.
• Regulatory & Clinical Risks: Success hinges on clinical data generation and regulatory feedback—any setbacks in trials or regulatory review could materially impact share price.
• Market Float & Trading: The reported market float and active trading on Nasdaq ensure liquidity, but also mean that price movements can be significant in response to news, clinical milestones, or broader market conditions.
• No Incorporation by Reference: The report explicitly states that no documents are incorporated by reference, meaning all relevant information is contained within the filing.

Potential Share Price Movers

The completion of a large asset acquisition and subsequent issuance of millions of shares is highly price-sensitive. Investors should monitor:

• Future clinical trial results and regulatory developments on the newly acquired assets.
• Progress on capital-efficient development strategies and potential partnerships or funding announcements.
• Any further updates regarding pipeline prioritization or commercialization plans.
• Changes in market float and trading volumes, as these can amplify price movements.

These factors are likely to have substantial impact on Tempest’s share value and investor sentiment. The company’s approach to managing cash and extending operational runway is also critical in the current market environment.